AtremoPlus Natural L-Dopa: Positive and measurable results!

In this new newsletter, we will delve deeper into our quest to make things measurable and thus quantify the improvements following the use of AtremoPlus.

“Advances in medicine often result from the ability to accurately measure biological phenomena (…). Biomarkers are essential tools in our arsenal (…)”
Dr. Elizabeth Blackburn, Nobel Prize in Medicine 2009

Your feedback and experiences with AtremoPlus are crucial to us, as they reflect your firsthand experience. Therefore, we always appreciate hearing from you through your testimonials on our dedicated page:…

Moreover, in our surveys, we aim to quantify your experiences because they are powerful and valuable both individually and collectively. This approach aims to highlight that many AtremoPlus users report significant improvements in the specific areas addressed by the surveys.

In this newsletter, we will explore the measurements conducted during our dietary supplement’s preclinical and clinical studies, which allow us better to understand the underlying biological mechanisms behind your positive experiences.

In the first part, we will address the improvement of certain parameters commonly referred to as biomarkers, demonstrated during these studies.

In the second part, we will go even further by examining the correlation between the improvement of these biomarkers and a real enhancement in cognitive and motor performance among study participants.
Ultimately, the key point is that these improvements contribute to a better quality of life for you.

1- The Fascinating World of Biomarkers

Biomarkers are measurable indicators in the body, such as molecules or biological signals, which can be used to assess a person’s health status or the progression of dysfunction.
In other words, they are observable or measurable elements that provide valuable information about a person’s health, thus helping to understand what is happening inside the body. This information is crucial for taking appropriate measures to restore balance, or at least improve dysfunction as much as possible.

The search for biomarkers is akin to an investigation conducted by an attentive detective. Each biomarker is like a precious clue, a piece of the puzzle that helps the detective understand the dysfunction or improvement of a person’s body. Like a good detective, researchers study these biomarkers carefully, connecting them to each other to unravel the mystery of health and disease.

What biomarkers are improved in the studies conducted on our dietary supplement?

Among a significant list of clinical tests and biomarkers recorded during preclinical and clinical trials, we have selected for this newsletter a sample of the most significant biomarkers.

1. Dopamine levels: Measurement of dopamine levels, essential for motor control, cognitive performance, and emotional state.
Result 1 hour after taking 5g of AtremoPlus: More than 90% of people diagnosed with Parkinson’s disease at the time of diagnosis have dopamine levels below 20 pg/mL, which is very low. AtremoPlus induces dopamine synthesis, leading to a 100-200% increase in dopamine levels in nearly 98% of people for up to 6 hours. Thus, two doses of 5g per day often cover relatively long periods.

2. Noradrenaline level: Measurement of noradrenaline levels, often underestimated yet essential for motor control, memory, and mood regulation.
Result 1 hour after taking 5g of AtremoPlus: Significant increases in noradrenaline levels were observed during studies. Thus, two doses of 5g per day often cover relatively long periods. Given the importance of this biomarker, we will provide the average percentage increase of study participants in the newsletter dedicated to noradrenaline in an upcoming issue.

3. Alpha-synuclein protein: Key marker of the disease, its abnormal accumulation is associated with observed brain lesions closely linked to a phenomenon called methylation.
Result after taking AtremoPlus: Significant epigenetic improvement in global methylation up to 67.5% was observed during studies. See also newsletter number 10 below.

4. Electrophysiological activity: Assessment of brain electrical signals disrupted in Parkinson’s patients. This includes abnormal electroencephalogram (EEG).
Result 1 hour after taking 5g of AtremoPlus: Improvements in brain waves were observed during studies, notably a decrease in very slow waves (Delta and Theta) associated with chronic fatigue and daytime sleepiness, replaced by Alpha waves, representing a wakeful and relaxed state. (See photo below and newsletter 19 below). Thus, two doses of 5g per day often cover relatively long periods.

5. Oxidative stress biomarkers: Indicators of cellular stress, such as lipid peroxidation, involved in the progression of organism degeneration.
Result after taking AtremoPlus: During studies, an average improvement of 32.1% in oxidative stress consequences was observed.

6. Chronic inflammation biomarkers: Measurement of markers related to chronic inflammation, associated with organism degeneration.
Result after taking AtremoPlus: During studies, a significant decrease of 26% in inflammation markers was observed, with even higher reduction for a biomarker involved in the inflammatory process called prolactin at 38.7%.

7. Stress hormones like cortisol: Measurement of cortisol, a hormone for acute or chronic stress, to evaluate stress response weakening the person and their body.
Result after taking AtremoPlus: During studies, a significant decrease in stress hormones was observed, with a 26.4% reduction in cortisol levels.

The improvements shown by these measures demonstrate very positive effects at various levels of the organism, thus creating a synergy conducive to reclaiming ground and enhancing quality of life.

It is noteworthy that another fundamental biomarker is our genes. Clinical studies have clearly revealed significant differences, particularly in the ability to use, or more precisely metabolize, L-dopa. Therefore, the effects of taking AtremoPlus vary from person to person and manifest at different intensities depending on the specific issues encountered. Note that the same applies to synthetic L-dopa, which is more or less well metabolized depending on the person’s genetic profile.

Due to these differences in metabolism, among other factors related to L-dopa, we recommend taking 10g per day. Some individuals already achieve excellent results with 5g per day, while others may require 15-20g per day. In fact, most people achieve excellent results with 10g per day.

2- What is the impact of improving biomarkers on people’s lives?

Indeed, it is interesting to observe significant improvements in certain biomarkers crucial for the proper functioning and maintenance of important functions in our body.

However, the natural question that arises is: what is the real impact of these biomarker improvements, particularly on motor function, cognitive abilities, emotional state of users, and hence their quality of life? And how can these improvements be quantified?

Improvement in brain waves and its impact on real life

As we demonstrated in our latest newsletter, one of the interesting biomarkers to observe in Parkinson’s disease, as well as in Alzheimer’s disease, is the activity of brain waves.
Indeed, our brain oscillates at different speeds depending on our needs.
For example, when we face danger, our brain oscillates very quickly on Gamma waves, which allows us to take appropriate measures to quickly move away from danger.
When we are focused on a complex task, our brain oscillates on Beta waves.
Alpha waves, situated in the middle of the spectrum, correspond to a relaxed wakeful state. The slowest waves, Delta waves, are present during deep sleep, while Theta waves are ideal, for example, during a state of deep meditation.

Delta and Theta waves are generally essential and important during the night or during meditation. However, if they are excessively present during the day, as is the case in many people with Parkinson’s disease, this results in chronic fatigue and daytime sleepiness.

Our clinical study with our supplement focuses on three groups of people at different stages of Parkinson’s disease:

– People with Parkinson’s without cognitive impairment
– People with Parkinson’s with mild cognitive impairment
– People with Parkinson’s with dementia

As observed, very slow Delta and Theta waves give way to faster Alpha waves, reflecting a wakeful state while remaining relaxed and unstressed.

ATremoPlus ondes cerebrales - AtremoPlus Natural L-Dopa: Positive and measurable results!

Image: The red areas correspond to slow Theta waves, often associated with drowsiness, while Alpha waves, shown in green, are faster. They indicate a state of relaxation while remaining awake and alert.

Taking 5 grams twice a day (four doses daily), as practiced by the majority of our clients, promotes an increase in fast Alpha waves oscillating in your brain twice a day, making you both more awake and relaxed, while reducing the very slow Delta and Theta waves associated with drowsiness.

The fundamental question is whether the acceleration of Delta and Theta brain waves towards Alpha waves during the day translates into a real improvement in the person’s parameters.

To obtain observable data, a test was conducted before and after taking the dietary supplement. This is the UPDRS test (Unified Parkinson’s Disease Rating Scale). Widely recognized and used, this test evaluates various critical parameters, including motor skills, in people with Parkinson’s disease. During this test, significant improvement was achieved for all groups, specifically as follows:

Group A (Parkinson’s without cognitive impairment):
The UPDRS motor score shows an average improvement of 50.67% for this group.
(letters ABC to avoid confusion with our groups 1, 2, and 3)

Group B (Parkinson’s with mild cognitive impairment):
The UPDRS motor score shows an average improvement of 46.15% for this group.

Group C (Parkinson’s with dementia):
The UPDRS motor score shows an average improvement of 20.63% for this group.

These data clearly demonstrate that the improvement of biomarkers is closely linked to the improvement of motor skills, among other things. For example, there is a reduction in rigidity, a decrease in slow movements, and fewer freezing episodes, among others.

What is particularly moving for us is that these improvements were even observed in Group C, composed of people with Parkinson’s disease and a certain degree of dementia. For these individuals and their families, this situation is often very challenging, and while the test score improvement of over 20% on average is lower than that of the other two groups, it is nonetheless remarkable.

It is indeed interesting to note the significant improvements in certain biomarkers essential for the proper functioning and maintenance of important functions in our body.

However, the natural question that arises is: what is the real impact of these biomarker improvements, particularly on motor and cognitive abilities, as well as on the emotional state of users, and therefore their quality of life? And how can these improvements be quantified?

The Improvement of Methylation and Its Impact on Real Life

In one of our previous newsletters, we highlighted the potential reversibility of certain alterations in gene expression through epigenetics, a fascinating field of research. This approach offers, among other things, the possibility of positively impacting the misfolding of certain proteins in the brain, thereby reducing the formation of harmful aggregates, as demonstrated in our newsletter number 10.

A crucial element in this process is methylation, an essential phenomenon for the regulation of gene expression. The findings of a recent study on AtremoPlus are particularly promising, as they highlight the role of the active ingredients in this Vicia faba-based dietary supplement in modulating DNA methylation, especially in cases of Parkinson’s and Alzheimer’s.

This study also highlighted a positive correlation between MMSE (Mini-Mental State Examination) scores and overall improvement in methylation.
In other words, improved methylation levels are associated with better MMSE results in aspects such as temporal and spatial orientation, short-term memory, attention, language, and the ability to follow simple instructions.

Better cognitive performance is a considerable asset for a person’s quality of life.

Studies Are Consistent with Surveys and Your Testimonials

Although much remains to be discovered about our body’s mechanisms, individual testimonials from AtremoPlus users show a correlation with the results of collective surveys as well as data from studies and biomarkers.

Of course, the metabolism of certain bioactive principles, including L-Dopa, varies from person to person, as demonstrated by studies conducted by our teams on these genetic biomarkers. However, it is fascinating to note that the full spectrum of active ingredients present in natural sources such as Vicia faba acts very differently from an isolated molecule.

This is why, for example, you can find combinations such as Vitamin B6 with magnesium in pharmacies, as these two elements act synergistically, enhancing their respective effects. You can refer to our newsletter number 10 for more on the joint action of L-Dopa and Carbidopa and other trace elements from Vicia faba by clicking on the link below.

In our next newsletter, we will explore a powerful, fascinating, and fundamental theme, often underestimated yet equally measurable.
However, without even a basic understanding of this phenomenon, you might miss out on an exceptional and powerful tool, which is also entirely free. That is why we wish to explore it in detail with you.

In the meantime, we would like to give the floor to Bernd, who shared his experience with AtremoPlus:

“BEFORE AtremoPlus, energy level (EL) was very fluctuating, quite low at certain times of the day (for example, after meals or in the early evening).
AFTER AtremoPlus, rapid strengthening of the energy level (EL), (after about 30 to 45 minutes), leading to a marked improvement in mobility.”

This content may be important for people who need this natural solution. Thanks for sharing !


By clicking on the button below, I leave the information site:

Please note that this blog provides information about our dietary supplement AtremoPlus and related topics.

This blog is not intended to provide medical advice.
If you have any medical questions, please contact your healthcare professional.

References :

He, Xuetao, et al. “The patterns of EEG changes in early-onset Parkinson’s disease patients.” International Journal of Neuroscience 127.11 (2017): 1028-1035.

Bhat, Shreya, et al. “Parkinson’s disease: Cause factors, measurable indicators, and early diagnosis.” Computers in biology and medicine 102 (2018): 234-241.

Shirahige, Livia, et al. “Quantitative electroencephalography characteristics for Parkinson’s disease: a systematic review.” Journal of Parkinson’s Disease 10.2 (2020): 455-470.

Stumpf, Kilian, et al. “Effects of Parkinson’s disease on brain-wave phase synchronisation and cross-modulation.” Europhysics Letters 89.4 (2010): 48001.

Bose, A. and Beal, M.F. (2016), Mitochondrial dysfunction in Parkinson’s disease. J. Neurochem., 139: 216-231

Winklhofer, Konstanze F., and Christian Haass. “Mitochondrial dysfunction in Parkinson’s disease.” Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1802.1 (2010): 29-44.

Exner, Nicole, et al. “Mitochondrial dysfunction in Parkinson’s disease: molecular mechanisms and pathophysiological consequences.” The EMBO journal 31.14 (2012): 3038-3062.

Abou-Sleiman, Patrick M., Miratul MK Muqit, and Nicholas W. Wood. “Expanding insights of mitochondrial dysfunction in Parkinson’s disease.” Nature Reviews Neuroscience 7.3 (2006): 207-219.

Latif, Saad, et al. “Dopamine in Parkinson’s disease.” Clinica chimica acta 522 (2021): 114-126.

Espay, Alberto J., Peter A. LeWitt, and Horacio Kaufmann. “Norepinephrine deficiency in Parkinson’s disease: the case for noradrenergic enhancement.” Movement Disorders 29.14 (2014): 1710-1719.

Sathya Prabhu, D., and V. Devi Rajeswari. “Nutritional and biological properties of Vicia faba L.: A perspective review.” International Food Research Journal 25.4 (2018): 1332-1340.

Dhull, Sanju Bala, et al. “A review of nutritional profile and processing of faba bean (Vicia faba L.).” Legume Science 4.3 (2022): e129.

Ryu, Jaihyunk, et al. “Fatty acid composition, isoflavone and L-3, 4-dihydroxyphenylalanine (L-dopa) contents in different parts of faba bean (Vicia faba) genotypes.” Plant breeding and Biotechnology 5.4 (2017): 314-324.

Kempster, P. A., and M. L. Wahlqvist. “Dietary factors in the management of Parkinson’s disease.” Nutrition reviews 52.2 (1994): 51.

Nikkhah, Karim, et al. “Efficacy and safety of Vicia faba L. extract compared with levodopa in management of Parkinson’s disease and an in-silico phytomedicine analysis.” International Journal of Ayurvedic Medicine 14.3 (2023): 794-800.

Rijntjes, Michel. “Knowing your beans in Parkinson’s disease: a critical assessment of current knowledge about different beans and their compounds in the treatment of Parkinson’s disease and in animal models.” Parkinson’s Disease 2019 (2019).

Vered, Y., et al. “Bioavailability of levodopa after consumption of Vicia faba seedlings by Parkinsonian patients and control subjects.” Clinical neuropharmacology 17.2 (1994): 138-146.

Morais, L. C. S. L., J. M. Barbosa-Filho, and R. N. Almeida. “Plants and bioactive compounds for the treatment of Parkinson’s disease.” Arquivos Brasileiros de Fitomedicina Científica 1 (2003): 127-132.

Shetty, Kalidas, Reena Randhir, and Dipayan Sarkar. “Bioprocessing strategies to enhance L-DOPA and phenolic bioactives in the fava bean (Vicia faba).” Functional Foods and Biotechnology. CRC Press, 2019. 99-114.

Leave a Reply

Your email address will not be published. Required fields are marked *